Pricing drugs, selling hype and how we got here in the first place
May 15, 2018 - 15:46
Radio and PodcastLive Radio & Podcasts
Science & Medicine
Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place
In an episode free of Valeant Pharmaceuticals and Martin Shkreli, Fierce editors discuss a Senate investigation into Gilead Sciences' pricing of the hepatitis C drug Sovaldi, BioMarin's efforts to win approval for a rare...
About This Episode
Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place is an episode from FierceBiotech Radio. In an episode free of Valeant Pharmaceuticals and Martin Shkreli, Fierce editors discuss a Senate investigation into...
Podcast
This episode belongs to FierceBiotech Radio.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Dec 3, 2015, 24:31 long, audio available.
Related Episodes
Continue listening to more episodes from FierceBiotech Radio.
